^
Association details:
| Biomarker: | EPAS1 overexpression |
|---|---|
| Cancer: | Clear Cell Renal Cell Carcinoma |
| Drug: | pazopanib (Multi-tyrosine kinase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma
Excerpt:
When we examined PFS among both groups with low and high HIF2α staining there was no statistically significant difference between the two groups...Interestingly, we identified a higher expression of HIF1α than HIF2α. Nevertheless, the level of expression of HIF1α and HIF2α was not associated with clinical response to pazopanib.
DOI:
10.1158/1078-0432.CCR-13-0491
Trial ID:
